Real-World Experience with the Available Outpatient COVID-19 THErapies in Patients with canceR (CO.THER).

IF 4.5 2区医学 Q1 ONCOLOGY

Cancers Pub Date : 2025-03-17 DOI:10.3390/cancers17060999

Angioletta Lasagna, Giulia Gambini, Catherine Klersy, Simone Figini, Sofia Marino, Paolo Sacchi, Paolo Pedrazzoli

{"title":"Real-World Experience with the Available Outpatient COVID-19 THErapies in Patients with canceR (CO.THER).","authors":"Angioletta Lasagna, Giulia Gambini, Catherine Klersy, Simone Figini, Sofia Marino, Paolo Sacchi, Paolo Pedrazzoli","doi":"10.3390/cancers17060999","DOIUrl":null,"url":null,"abstract":"Background/objectives: Cancer represents an important risk factor for acquiring severe acute respiratory syndrome by Coronavirus-2 (SARS-CoV-2) and subsequent hospitalization. The utility of early antiviral therapies, including their protective effect on long COVID outcomes, in cancer patients has not yet been clearly demonstrated. We conducted the CO.THER study (COVID-19 THErapies in patients with canceR) to address this knowledge gap.Methods: We designed an ambispective single-center cohort study. We collected clinical and oncological data from the hospital's electronic patient records at the start of COVID-19 therapy (T0), seven days after T0 (T1), two weeks after T0 (T2), one month after T0 (T3), three months after T0 (T4), six months after T0 (T5), and twelve months after T0 (T6). The primary endpoint of this ambispective single-center cohort study was the rate of hospitalization for COVID-19 disease within 14 days in cancer patients using anti-SARS-CoV-2 early therapies. The proportion of hospitalizations within 14 days (primary endpoint) was computed together with its exact binomial 95% confidence interval (95%CI).Results: 131 patients' records (53M [40.5%], 78F, [59.5%]; median age 62.45, interquartile range [IQR] 56-71) were enrolled. As shown by the Kaplan-Meier hospitalization-free estimate, only three patients (2.1%) were hospitalized for a COVID-19 related cause within 14 days of starting early treatment (95%CI 0.5-6.6%). The cumulative survival probability beyond 12 months in hospitalization-free patients was 98% (95%CI 93-99%). Twelve patients (9.2%) reported another COVID-19 infection during the follow-up and they were all retreated with Nirmatrelvir-Ritonavir. The cumulative reinfection-free survival was 90% at 12 months (95%CI 83-95%). Further, 15 patients of the 123 evaluable at 3 months (median age 51 years, IQR 40-68) reported long COVID symptoms (12.2%, 95%CI 7.0-19.3%).Conclusions: Our data demonstrate a low rate of hospitalization and reassuring data on safety in this cohort of high-risk subjects.","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940374/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17060999","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objectives: Cancer represents an important risk factor for acquiring severe acute respiratory syndrome by Coronavirus-2 (SARS-CoV-2) and subsequent hospitalization. The utility of early antiviral therapies, including their protective effect on long COVID outcomes, in cancer patients has not yet been clearly demonstrated. We conducted the CO.THER study (COVID-19 THErapies in patients with canceR) to address this knowledge gap.

Methods: We designed an ambispective single-center cohort study. We collected clinical and oncological data from the hospital's electronic patient records at the start of COVID-19 therapy (T0), seven days after T0 (T1), two weeks after T0 (T2), one month after T0 (T3), three months after T0 (T4), six months after T0 (T5), and twelve months after T0 (T6). The primary endpoint of this ambispective single-center cohort study was the rate of hospitalization for COVID-19 disease within 14 days in cancer patients using anti-SARS-CoV-2 early therapies. The proportion of hospitalizations within 14 days (primary endpoint) was computed together with its exact binomial 95% confidence interval (95%CI).

Results: 131 patients' records (53M [40.5%], 78F, [59.5%]; median age 62.45, interquartile range [IQR] 56-71) were enrolled. As shown by the Kaplan-Meier hospitalization-free estimate, only three patients (2.1%) were hospitalized for a COVID-19 related cause within 14 days of starting early treatment (95%CI 0.5-6.6%). The cumulative survival probability beyond 12 months in hospitalization-free patients was 98% (95%CI 93-99%). Twelve patients (9.2%) reported another COVID-19 infection during the follow-up and they were all retreated with Nirmatrelvir-Ritonavir. The cumulative reinfection-free survival was 90% at 12 months (95%CI 83-95%). Further, 15 patients of the 123 evaluable at 3 months (median age 51 years, IQR 40-68) reported long COVID symptoms (12.2%, 95%CI 7.0-19.3%).

Conclusions: Our data demonstrate a low rate of hospitalization and reassuring data on safety in this cohort of high-risk subjects.

查看原文本刊更多论文

坎塞洛（CO.THER）患者使用现有门诊 COVID-19 疗法的实际体验。

背景/目的：癌症是由冠状病毒-2 （SARS-CoV-2）感染严重急性呼吸综合征并随后住院治疗的重要危险因素。早期抗病毒治疗在癌症患者中的效用，包括其对COVID - 19长期预后的保护作用，尚未得到明确证明。我们开展了CO.THER研究（癌症患者的COVID-19治疗），以解决这一知识差距。方法：我们设计了一项双视角单中心队列研究。我们在COVID-19治疗开始（T0）、T0 （T1）后7天、T0 （T2）后2周、T0 （T3）后1个月、T0 （T4）后3个月、T0 （T5）后6个月和T0 （T6）后12个月从医院的电子病历中收集临床和肿瘤数据。这项双视角单中心队列研究的主要终点是使用抗sars - cov -2早期治疗的癌症患者在14天内因COVID-19疾病住院的比率。计算14天内住院的比例（主要终点）及其精确的二项95%置信区间（95% ci）。结果：131例患者记录中，3m为53M [40.5%]， f为78F [59.5%]；中位年龄62.45岁，四分位间距[IQR] 56-71)。Kaplan-Meier无住院估计显示，在开始早期治疗的14天内，只有3名患者（2.1%）因COVID-19相关原因住院（95%CI 0.5-6.6%）。无住院患者超过12个月的累积生存率为98% （95%CI 93-99%）。12例（9.2%）患者在随访期间再次出现COVID-19感染，均使用尼马特利韦-利托那韦治疗。12个月累计无再感染生存率为90% （95%CI 83-95%）。此外，123例3个月时可评估的患者中有15例（中位年龄51岁，IQR 40-68）报告了较长的COVID症状（12.2%,95%CI 7.0-19.3%）。结论：我们的数据表明，在这组高风险受试者中，住院率低，安全性数据令人放心。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancers Medicine-Oncology

CiteScore

8.00

自引率

9.60%

发文量

5371

审稿时长

18.07 days

期刊介绍： Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.